Latest Clinical Adoption News

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Microba Life Sciences reports robust year-on-year growth in microbiome testing volumes and revenue, advancing towards regional break-even in Australia and the UK while progressing its therapeutic pipeline.

Microba Life Sciences reports a 90% year-on-year increase in core microbiome test volumes, driving a 123% rise in core testing revenue to $2.1 million, while advancing clinical adoption and cost efficiencies.

Nova Eye Medical has reported a record US$6.1 million in global sales for the December 2025 quarter, marking a 38% year-on-year increase and strong momentum across key markets. The company’s innovative iTrack™ technology continues to drive growth, supported by expanded manufacturing capacity and advancing clinical programs.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

BCAL Diagnostics has launched its Avantect pancreatic and ovarian cancer tests in Australia, alongside expanding clinical data and establishing a national registry for its BREASTESTplus breast cancer test.

UC San Diego Health has begun clinical use of 4DMedical’s CT – VQ™, marking the fourth leading US academic medical centre to adopt this innovative lung imaging technology since FDA clearance. This milestone underscores 4DMedical’s rapid commercial traction and growing influence in respiratory diagnostics.

BlinkLab Limited has secured independent scientific validation for its smartphone-based autism diagnostic technology through publication in the prestigious journal Autism Research, marking a significant milestone ahead of its FDA regulatory trial.

Memphasys has secured CE Mark approval for its Felix™ sperm selection system, enabling full commercial rollout across Europe and activating multi-year contracts worth over A$1.3 million. This milestone signals the company’s transition into a revenue-scaling phase with global growth ambitions.

TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.